Importantly, combining systemic Ptgs2 loss does not promote additional benefits on Ptgs2-depleted tumor growth and mice survival, suggesting that tumor-derived PGE2 is sufficient to drive T cell-dependent immunosuppression and thereby cancer progression [113]. This evidence concerns the gene PTGS2 and neoplasm.